

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



Final Appraisal Recommendation

Advice No: 1518 – September 2018

**Octreotide (Sandostatin® LAR®) 10 mg, 20 mg and 30 mg
powder and solvent for suspension for injection**

Limited submission by Novartis Pharmaceuticals UK Ltd

Recommendation of the All Wales Medicines Strategy Group

Octreotide (Sandostatin® LAR®) is recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.

Additional note(s):

- AWMSG considered that octreotide (Sandostatin® LAR®) satisfied the AWMSG criteria for a medicine developed specifically for rare diseases.
- AWMSG were of the view that prescribing should be initiated by a specialist clinician within secondary care.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3732), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1518:

Octreotide (Sandostatin® LAR®) 10 mg, 20 mg and 30 mg powder and
solvent for suspension for injection. September 2018.